Skip to content

Study on the Response to Tetanus Vaccination of People Living With HIV

Study on the Response to Tetanus Vaccination of People Living With HIV

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03853681
Acronym
VACTEVIH
Enrollment
210
Registered
2019-02-26
Start date
2019-03-11
Completion date
2020-02-24
Last updated
2020-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Brief summary

The response to primary tetanus immunization of HIV-infected children is lower than that of uninfected children. Response to tetanus toxoid (TT) booster doses in adults living with HIV who have received primary vaccination prior to infection is not known. Currently, it is recommended to have a TT booster for people living with HIV (PLHIV) every 10 years. In general population, this recall is made only at 25, 45 and 65 years, then every 10 years.

Interventions

additional blood sampling

Sponsors

Centre Hospitalier de Niort
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Person aged ≥ 18 years * Person infected with HIV followed in the infectious diseases department of CH Niort * Born in France * Affiliate or beneficiary of a social security scheme * Being able to give free and informed consent to participation in research

Exclusion criteria

* Persons with a contraindication to tetanus vaccination * Persons under guardianship or curatorship or without civil law

Design outcomes

Primary

MeasureTime frameDescription
the vaccine response to tetanus vaccinationMonth 6An anti-tetanus IgG level\> 0.1 is considered long-term protective. An anti-tetanus IgG level between 0.01 and 0.1 is considered protective in the short term. The measurement of the vaccine response will be correlated with the age of the last VAT recall (\<10 years, between 10 and 20 years,\> 20 years and unknown)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026